Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

OHSU researcher says FDA could broaden access to results of clinical drug trials

29.12.2004


Information submitted via new drug applications could easily be made accessible to the public, he says



A researcher at Oregon Health & Science University and the Portland Veterans Affairs Medical Center is calling upon the U.S. Food and Drug Administration (FDA) to share more information provided by pharmaceutical companies regarding their clinical drug trials. This database could be freely accessible to health care providers, researchers and the public. Such a move would be cost-effective and could work in conjunction with other national clinical registry and results database efforts already under way, said Erick Turner, M.D., assistant professor of psychiatry, and physiology and pharmacology in the OHSU School of Medicine.

Turner, a former clinical reviewer of psychotropic drugs for the FDA, put forth his recommendations in the essay "A Taxpayer-Funded Clinical Trials Registry and Results Database: It Already Exists Within the U.S. Food and Drug Administration," published online Dec. 28, 2004, in the Public Library of Science Medicine Journal, a peer-reviewed, open-access publication.


"Over the past few years, there has been growing concern about selection bias in the way clinical trials results are published," said Turner. The debate intensified, he said, with a summer 2004 lawsuit against GlaxoSmithKline alleging that company hid data regarding the safety and efficacy of serotonin reuptake inhibitors given to pediatric patients with depression.

The two most frequently suggested remedies for the selective reporting of clinical trials results have been to register all clinical trials and to make their results publicly available. "Registries have been called for since 1974," said Turner, "and hundreds have already been established." However, said Turner, the current registries usually aren’t coordinated and participation is voluntary. Consequently, not all clinical trial results are listed and those that are may be incomplete. "I suggest that we increase public access to the clinical trials registry and results database that has long existed within the FDA," said Turner. "This would provide a lot of bang for the taxpayer buck.

"If a drug company wants to market a drug for a particular use or indication in the U.S., it must do studies and prove to the FDA that it is safe and effective for that indication. But before it can do those studies, it must register them with the FDA. Because the FDA is made aware of these studies in advance, the study sponsor cannot pretend that a study that turned out negative did not exist. So the FDA reviews all major studies, positive or negative, published or unpublished.

"In accordance with the Electronic Freedom of Information Act, over the past several years, the FDA has been posting the review documents for some approved drug-indication combinations on its Web site. Unfortunately, these reviews are only sporadically available. I believe that the FDA could make all -- not just some -- NDA [new drug application] reviews, at least for approved NDAs, available in the public domain," said Turner. Staffing at the FDA might need to be increased,, acknowledged Turner. Also, simple formatting changes could make the FDA reviews much more user-friendly, he said.

"The idea of an FDA clinical trial results database could be complementary to proposals by the American Medical Association (AMA) and other groups," Turner explained. The AMA, for example, has proposed creation of a registry that is comprehensive, whereas the FDA registry and results database would be restricted to those trials aimed at supporting U.S. drug marketing approval or a change in labeling in the United States.

"Despite the limitations of the FDA’s database, making it public is a strategy that could be implemented both rapidly and easily by building upon existing infrastructure," said Turner. "While we wait for new proposals, such as the AMA’s, to be implemented, we already have at our disposal a trove of in-depth and unbiased information on many, if not most, drugs currently marketed in the United States. This would provide health care providers, researchers and the public with a more balanced and complete view of the efficacy and safety of our drugs. It should ultimately benefit the public health."

Tamara Hargens | EurekAlert!
Further information:
http://www.ohsu.edu

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>